Management of Anemia, Bone and Mineral Disorders, and Vitamin D Deficiency in End-Stage Renal Disease

Anemia Management

Iron deficiency is a common cause of anemia in CKD and should be evaluated with regular monitoring of CBC, iron/TIBC (TSAT), and ferritin 3
Complete blood count should be monitored every 3 months as planned, with concurrent iron studies to guide therapy 3

The patient's low calcium level requires correction as hypocalcemia should not be ignored 4, 1
Calcium recommendations should be personalized based on the patient's mineral metabolism status, overall calcium balance, and bone health 4
Calcium supplementation should be approached cautiously to avoid excessive calcium loading while addressing hypocalcemia 1, 2

Sodium bicarbonate (650 mg 2-3 times daily) is appropriate for treating metabolic acidosis 1
Correction of metabolic acidosis helps improve bone health by reducing bone resorption that occurs with chronic acidosis 1

Monitor serum phosphate levels regularly as hyperphosphatemia is common in ESRD 1
If hyperphosphatemia develops, dietary phosphate restriction and non-calcium-based phosphate binders should be considered 2
Use of calcium-based phosphate binders should be restricted in patients with hyperphosphatemia across the CKD spectrum 5

For controlling PTH, low-dose active vitamin D could be a helpful supplement to nutritional vitamin D and dietary phosphate restriction 4, 6

Regular PTH monitoring is essential, with treatment focused on progressively rising or persistently elevated levels rather than a single elevated value 7
Bone-specific alkaline phosphatase can help diagnose mineralization disorders 8
Consider DXA BMD testing as it predicts fractures in CKD patients with comparable accuracy as in the general population 8

Confirm follow-up with nephrologist to coordinate comprehensive CKD-MBD management 1
Complete hepatitis B vaccination at health department as planned, with subsequent serologic testing to confirm immunity 3
Assess response to therapy with regular laboratory monitoring of mineral metabolism parameters, anemia markers, and kidney function 1, 5

Avoid overtreatment of secondary hyperparathyroidism, as low bone turnover can result from excessive suppression of PTH 9
PTH is not a bone turnover marker and must be assessed in relation to calcium, phosphate, and 25(OH)-vitamin D levels 4
The interplay among biochemical variables (serum phosphate, calcium, and PTH) is complex, and therapeutic interventions aimed at improving one parameter often have unintended effects on others 5
Recognize that vitamin D supplementation may increase risk of hypercalcemia, requiring careful monitoring 7